Overexpression of lncRNA PTENP1 suppresses glioma cell proliferation and metastasis in vitro.
glioma
invasion
lncRNA PTENP1
migration
proliferation
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
8
1
2019
pubmed:
8
1
2019
medline:
8
1
2019
Statut:
epublish
Résumé
Glioma is one of the most common malignancies of the central nervous system in adults. The lncRNA PTEN pseudogene-1 (PTENP1) has been reported to play an important role in the development and progression of various cancers. However, the molecular mechanism by which lncRNA PTENP1 affects the development and progression of gliomas remains unclear. The levels of PTENP1 expression in glioma tissues and normal brain tissues were detected by quantitative real-time PCR. Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine staining assays were performed to detect cell proliferation. Flow cytometry was used to analyze cell cycle progression. Transwell assay and scratch test were used to detect cell migration and invasion, and Western blot studies were performed to detect protein expression. Our results showed that expression of lncRNA PTENP1 was decreased in glioma tissues when compared with normal brain tissues. Overexpression of PTENP1 suppressed SHG44 and U251 cell proliferation and significantly decreased the numbers of S-phase cells. Furthermore, the invasion and migration abilities of SHG44 and U251 cells were reduced after being transfected with a PTENP1 overexpression plasmid. Overexpression of PTENP1 induced the expression of p21 protein and suppressed the p38 signaling pathway. Our study investigated the function of PTENP1 in glioma and provided new insights for treating that malignancy.
Sections du résumé
BACKGROUND
BACKGROUND
Glioma is one of the most common malignancies of the central nervous system in adults. The lncRNA PTEN pseudogene-1 (PTENP1) has been reported to play an important role in the development and progression of various cancers. However, the molecular mechanism by which lncRNA PTENP1 affects the development and progression of gliomas remains unclear.
MATERIALS AND METHODS
METHODS
The levels of PTENP1 expression in glioma tissues and normal brain tissues were detected by quantitative real-time PCR. Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine staining assays were performed to detect cell proliferation. Flow cytometry was used to analyze cell cycle progression. Transwell assay and scratch test were used to detect cell migration and invasion, and Western blot studies were performed to detect protein expression.
RESULTS
RESULTS
Our results showed that expression of lncRNA PTENP1 was decreased in glioma tissues when compared with normal brain tissues. Overexpression of PTENP1 suppressed SHG44 and U251 cell proliferation and significantly decreased the numbers of S-phase cells. Furthermore, the invasion and migration abilities of SHG44 and U251 cells were reduced after being transfected with a PTENP1 overexpression plasmid. Overexpression of PTENP1 induced the expression of p21 protein and suppressed the p38 signaling pathway.
CONCLUSION
CONCLUSIONS
Our study investigated the function of PTENP1 in glioma and provided new insights for treating that malignancy.
Identifiants
pubmed: 30613153
doi: 10.2147/OTT.S182537
pii: ott-12-147
pmc: PMC6306071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
147-156Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
FASEB J. 2018 Jun 6;:fj201800495RR
pubmed: 29874124
Nature. 2010 Jun 24;465(7301):1033-8
pubmed: 20577206
Oncol Res. 2018 Jul 5;26(6):869-878
pubmed: 29212574
Mol Cancer Ther. 2014 Dec;13(12):3086-97
pubmed: 25249556
Cancer Gene Ther. 2017 Jul;24(7):309-315
pubmed: 28731027
Bioorg Khim. 2013 Jul-Aug;39(4):445-53
pubmed: 24707726
Genes Dev. 1997 Apr 1;11(7):847-62
pubmed: 9106657
Neurochem Int. 2014 Nov;77:78-85
pubmed: 24887176
Melanoma Res. 2014 Aug;24(4):335-41
pubmed: 24892958
Oncogene. 1998 May 7;16(18):2403-6
pubmed: 9620558
PLoS One. 2014 Jan 23;9(1):e86295
pubmed: 24466011
Oncol Lett. 2017 Oct;14(4):4659-4662
pubmed: 29085464
Oncogene. 1999 Mar 4;18(9):1765-9
pubmed: 10208437
NPJ Precis Oncol. 2017 Sep 14;1(1):32
pubmed: 29872713
J Urol. 2013 Dec;190(6):2278-87
pubmed: 23845456
Med Hypotheses. 2013 Aug;81(2):319-21
pubmed: 23688743
J Cell Biochem. 2012 Jun;113(6):1868-74
pubmed: 22234798
Genes Dev. 1998 Dec 15;12(24):3882-8
pubmed: 9869641
J Cancer Res Clin Oncol. 2014 Dec;140(12):1989-95
pubmed: 24816785
Annu Rev Biochem. 2012;81:145-66
pubmed: 22663078
Cell Death Dis. 2018 Jun 4;9(6):673
pubmed: 29867200
Oncotarget. 2017 Nov 6;8(64):107859-107869
pubmed: 29296207